Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry

Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine ris...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yash S. Huilgol, Holly Keane, Yiwey Shieh, Robert A. Hiatt, Jeffrey A. Tice, Lisa Madlensky, Leah Sabacan, Allison Stover Fiscalini, Elad Ziv, Irene Acerbi, Mandy Che, Hoda Anton-Culver, Alexander D. Borowsky, Sharon Hunt, Arash Naeim, Barbara A. Parker, Laura J. van ‘T Veer, Athena Breast Health Network Investigators and Advocate Partners, Laura J. Esserman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80

Ejemplares similares